APPLICANTS: Ward et al. **SERIAL NO: 10/719,370**

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Docket No.: PTS-0070US.P1 (ISIS.038CP1)

Customer No.: 55389 GENTRAL FAX GENTER SEP 2 7 2006

Confirmation No.: 3593

Ward et al. Applicants:

Group Art Unit:

Serial No.:

10/719,370

1635

Filed:

November 21, 2003

Examiner:

Zara, Jane J.

Title:

MODULATION OF HIF1α AND HIF2α EXPRESSION

MS Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Examiner:

DECLARATION PURSUANT TO 37 C.F.R. § 1.131

I, Eric G. Marcusson, residing at 260 King Street #727, San Francisco, CA 94107, a citizen of the United States of America, do declare and state that:

- 1. I am an inventor of the subject matter claimed in the above-identified application.
- 2. I have reviewed the specification and claims as filed as well as the amended claims and new claims appearing in the response submitted herewith.
- 3. I have reviewed the Office Action mailed June 27, 2006. I understand the Examiner rejected claims 1, 3-8, 22-25, 33, 37 and 44 under 35 U.S.C. § 102(e) as being anticipated by Usman et al. (WO 2005/035759).
- This declaration is being submitted to establish that the subject matter described and currently claimed in the above-referenced patent application was conceived by me and reduced to practice in the United States prior to August 20, 2003, which is the earliest date to which the Usman et al. reference claims priority. In support of this conception and reduction to practice, a copy of a page from my laboratory notebook is provided herewith as Exhibit A. Dates and information not related to the completion of the claimed invention have been redacted. The

APPLICANTS: Ward et al. SERIAL NO: 10/719,370

DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

table has been labeled "Table 1" for the purpose of clarity in this declaration; however, in my original notebook page this table is unlabeled.

- a. As evidenced in Exhibit A, I designed a series of oligonucleotides to identify sequences that cross-react with HIF1 α and HIF2 α . The human HIF1 α and HIF2 α nucleotide sequences were compared to identify regions of identity. Based on this information, antisense oligonucleotides were designed which were perfectly complementary to HIF1 α or had no more than 4 mismatches to HIF1 α .
- b. Table 1 of Exhibit A lists the ISIS # of each oligonucleotide targeted to HIF1α and shows the sequence for each oligonucleotide. ISIS 330449 (SEQ ID NO: 446) was among the oligonucleotides designed in this study. In addition, twenty-three other oligonucleotides with a nucleotide sequence comprising at least 8 consecutive nucleobases of ISIS 330449 (SEQ ID NO: 446) were designed. These oligonucleotides are identified in Table 1 as ISIS #: 330447, 330448, 330450, 330451, 330452, 330453, 330454, 330455, 330456, 330457, 330458, 330459, 330460, 330461, 330462, 330463, 330464, 330465, 330466, 330467, 330468, 298698 and 326743.
- 5. In view of the foregoing evidence, prior to August 20, 2003, I conceived of and reduced to practice antisense oligonucleotides targeted to HIF1α (SEQ ID NO: 133), including oligonucleotides comprising at least 8 consecutive nucleobases of SEQ ID NO: 446.
- 6. I herby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 9/13/06

Eric G. Marcusson, Ph.D.

	~2/1.	1 14	ologic red to		deta from the	1	e that on	te do
	-0 17a .	11 1	mark.	-	and and	7	4-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	140
		MAN /			arc mea			•
								•
								•
					• • • • • • • • • • • • • • • • • • • •		,	
								
								•
					TABLE 1		•	
		·						-
-	1S/3 4	Designer	Notebook Page		Site ID Sequence	Marches She		
	330447 330446	EMARCUSS EMARCUSS	2362 2362	25 25	247086 TCATG GTCACATGGA TGAGT 247087 CTCAT GGTCACATGG ATGAG	TAUÈ TRUE	0 HEF1 and 2 cross reactors 0 HEF1 and 2 cross reactors	
	230449	emarcuse	2362	25	247088 CCTGA TOGTCACATG GATGA	TRUE	O HIF1 and 2 cross reactors	
	320480 330451	EMARCUSS EMARCUSS	2362 2362	25 25	247069 TTCCT CATGGTCACA TGGAT 247090 TYTCC TCATGGTCAC ATGGA	TRUE TRUE	O HIF1 and 2 group relations O HIF1 and 2 group reactors	
	330452	EMARCUSS	2382	25	247091 ATTTC CTCATGGTCA CATGG	TRUE	() HIF1 and 2 cross residers	•
	530453	EMARCUSS	2362	25	247082 CATTT CCTCATGGTC ACATG	TRUE	O HIF1 and 2 cross reactors O HIF1 and 2 cross reactors	
	830454 330456	EMARCUSS EMARCUSS	2362 2362	25 26	247093 TOATT TOCTCATRIF GACAT 247094 CTCAT TTCCTCATRIF TCACA	TRUE	D HIF1 and 2 cross reactors	
	330456	EMARCUSS	2362	25	247095 TCTCA TTTCCTCATG GTCAC	TRUE	O HIFT and 2 cross reactors	
	530457	EMARCUSS EMARCUSS	2362 2362	25 25	247096 CTCTO ATTTOCTCAT GGTCA 214487 TCTCT CATTTCCTCA TGGTC	TRUE	0 HIF1 and 2 cross reactions 0 HIF1 and 2 cross reactions	
	330458	EMARCUSS	2382	25	247007 TCATG GTCGCAGGGA TGAGT	TRUE	0 HIF1 and 2 cross reactors	
	330489	EMARCUSS	2362	25	247098 CTCAT GGTCGCAGGG ATGAG 247099 CCTCA TGGTCGCAGG GATGA	TRUE	0 HIF1 and 2 cross reactors 0 HIF1 and 2 cross reactors	
	330490 326743 Nor Unit	EMARCUSS BUILEMARCUSS	2382 2362	25 28	243656 TOCTO ATGGTCGCAG GGATG	TRUE	0 HIFT and 2 cross reactors	• ••
	330481	EMARCUSS	2362	25	247100 CTCCT CATGGTCGCA GGGAT	TRUE	0 HIF1 and 2 cross reaction	
	330482 330463	EMARCUSS EMARCUSS	2362 2362	26 25	247101 TOTCO TOATGGTOGO AGGGA 247102 ATOTO CTOATGGTOG CAGGG	TRUE	0 HIF1 and 2 cross resistors 9 HIF1 and 2 cross reactors	
	330484	EMARCUSS	2362	25	247103 AATOT COTCATOGTO GCAGG	TRUE	O HIFT and 2 cross reactors	
	230465 230486	EMARCUSS EMARCUSS	2382 2382	25 25	247104 GAATC TOCTCATGGT CGCAG 247105 ACGAA TOTCCTCATG GTCGC	TRUE	O HIF1 and 2 cross reactors O HIF1 and 2 cross reactors	
	890467	EMARCUSS	2362	25	247106 ÇAÇQA ATÇTOCTCAT GGTCG	TRUE	0 HIF1 and 2 cross reactors.	
	330488 330489	EMARCUSS EMARCUSS	2362 2362	25 25	247107 TGAGO AATGTÖCTÖA TÖGTÖ 247108 CACGO CAATGAAACC CTOCA	TRUE	0 HEF1 and 2 cross reactors 0 HEF1 and 2 cross reactors	• • • • • • • • • • • • • • • • • • • •
	330470	EMARCU68	2362	25	247100 AAADE CTCCAAGGET TTCAG	TRUE	0 HEF1 and 2 gross reactors	
					•			
								
					·			
•								
_								
	-			•				, , , , , , , , , , , , , , , , , , , ,
					<u> </u>			
			~					
_								. , ,

								.,
				-				·
			سر	-				
						-		
	<u> </u>	٠	and the same					
							-	

PAGE 23/23 * RCVD AT 9/27/2006 12:14:09 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/6 * DNIS:2738300 * CSID:7606033820 * DURATION (mm-ss):03-44